Endothelin: 20 years from discovery to therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.

Canadian Journal of Physiology and Pharmacology - Tập 86 Số 8 - Trang 485-498 - 2008
Matthias Barton1,2,3,4
1ERATO Yanagisawa Orphan Receptor Project, Japan Science and Technology Corporation, Tokyo, Japan
2Howard Hughes Medical Institute, Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, USA
3Klinik und Poliklinik für Innere Medizin, Departement für Innere Medizin, Universitätsspital Zürich, CH-8091 Zürich, Switzerland.
4Univ. of Zurich

Tóm tắt

Since its identification as an endothelial cell-derived vasoconstrictor peptide in 1988, endothelin-1, the predominant member of the endothelin peptide family, has received considerable interest in basic medical science and in clinical medicine, which is reflected by more than 20 000 scientific publications on endothelin research in the past 20 years. The story of endothelin is unique as the gene sequences of endothelin receptors and the first receptor antagonists became available within only 4 years of the identification of the peptide sequence.The first clinical study in patients with congestive heart failure was published only 3 years thereafter. Yet, despite convincing experimental evidence of a pathogenetic role for endothelin in development, cell function, and disease, many initial clinical studies on endothelin antagonism were negative. In many of these studies, study designs or patient selection were inadequate. Today, for diseases such as pulmonary hypertension, endothelin antagonist treatment has become reality in clinical medicine, and ongoing clinical studies are evaluating additional indications, such as renal disease and cancer. Twenty years after the discovery of endothelin, its inhibitors have finally arrived in the clinical arena and are now providing us with new options to treat disease and prolong the lives of patients. Possible future indications include resistant arterial hypertension, proteinuric renal disease, cancer, and connective tissue diseases.

Từ khóa


Tài liệu tham khảo

Agui T., 1994, Blood, 84, 2531, 10.1182/blood.V84.8.2531.2531

10.1038/348730a0

10.1139/Y08-058

10.1007/s11906-000-0064-5

10.1038/ncpneph0891

10.1007/s11906-001-0095-6

10.1097/00041552-199909000-00003

10.1006/bbrc.1997.7394

10.1073/pnas.95.24.14367

10.1126/science.281.5385.1986

Barton M., 2000, Hypertension, 35, 329, 10.1161/01.HYP.35.1.329

Barton M., 2000, J. Am. Soc. Nephrol., 11, 835, 10.1681/ASN.V115835

10.1016/S1357-2725(02)00307-2

10.1161/01.HYP.0000245138.09687.8a

Battistini B., 2006, Exp. Biol. Med. (Maywood), 231, 653

10.1046/j.1523-1755.2000.00023.x

10.1016/S0140-6736(98)09423-9

10.1038/ki.1993.263

10.1097/00041552-200101000-00001

10.1016/j.metabol.2005.05.019

10.1016/j.febslet.2006.09.032

10.1111/j.1524-6175.2007.07244.x

Boffa J.J., 2001, Hypertension, 37, 490, 10.1161/01.HYP.37.2.490

10.1097/00007890-199909270-00005

10.1517/14728214.10.4.747

Bruzzi I., 1997, J. Nephrol., 10, 179

10.1016/S0041-1345(97)01452-8

10.1073/pnas.96.12.6920

10.1016/j.micinf.2004.03.002

10.1161/01.HYP.0000103868.45064.81

Carrier M., 1991, Am. J. Physiol., 261, H1791

10.1111/j.1399-0012.2005.00357.x

10.1139/y03-052

10.1016/S0140-6736(01)06250-X

10.1152/ajprenal.00453.2004

10.1152/ajprenal.00442.2007

10.1053/euhj.2000.2557

10.1016/S0140-6736(05)77807-7

10.1124/pr.54.2.219

De Mey J.G., 1982, J. Pharmacol. Exp. Ther., 222, 166

10.1186/ar2190

10.1016/S0889-857X(03)00024-3

10.1136/ard.2005.048967

Dubin D., 1989, J. Vasc. Med. Biol., 1, 13

Dupuis J., 2000, Can. J. Cardiol., 16, 903

10.1016/S0140-6736(01)06298-5

10.1016/S0008-6363(00)00263-7

10.1038/sj.cdd.4402143

Ebihara I., 1996, Contrib. Nephrol., 118, 155, 10.1159/000425089

10.1016/0014-5793(92)80451-L

Ergul A., 2000, Hypertension, 36, 62, 10.1161/01.HYP.36.1.62

Ergul S., 1996, Hypertension, 28, 652, 10.1161/01.HYP.28.4.652

10.1161/CIRCULATIONAHA.104.528984

10.1097/00005344-198900135-00065

10.1016/S0041-1345(98)01241-X

10.1097/00007890-1999 01270-00025

10.1038/288373a0

10.1172/JCI8609

10.1139/Y08-028

10.1007/s004150050360

Gordon M.M., 1996, J. Rheumatol., 23, 788

10.1038/sj.bjc.6700750

Guo C., 1998, Circulation, 98, I-745

Hall J.E., 1994, Hypertension, 23, 381, 10.1161/01.HYP.23.3.381

10.1097/BOR.0b013e3282f13137

Hickey K.A., 1985, Am. J. Physiol., 248, C550, 10.1152/ajpcell.1985.248.5.C550

Hillier C., 2001, Circulation, 103, 1378, 10.1161/01.CIR.103.10.1378

10.1172/JCI119297

10.1183/09031936.00032407

Honing, M.L.H., Bouter, P.K., Ballard, D.E., and Rabelink, T.J. 2000. ABT-627, a selective ETA-receptor anatagonist, reduces proteinuria in patients with diabetes mellitus.InRegulation of Vascular Tone in Humans by Endothelium-derived Mediators [thesis]. Utrecht, The Netherlands: Elinkwijk BV: pp. 89–102.

10.1073/pnas.84.24.9265

10.1074/jbc.274.45.32469

10.1159/000048751

Julkunen H., 1991, Ann. Rheum. Dis., 50, 526, 10.1136/ard.50.7.526-c

10.1007/s001340000608

Kaisers U., 2008, Am. J. Physiol., 294, R601

Katoh T., 1990, Am. J. Physiol., 258, F397

10.1038/nrd2219

10.1146/annurev.pharmtox.41.1.851

Kelland N.F., 2006, Exp. Biol. Med. (Maywood), 231, 696

10.1136/hrt.2006.089250

10.1016/S0140-6736(95)91504-4

10.1097/01.fjc.0000152030.61620.57

10.1038/sj.bjp.0707516

10.1210/en.2005-1228

10.1016/S0272-6386(97)90004-4

Kohan D.E., 2006, Curr. Opin. Nephrol. Hypertens., 15, 34, 10.1097/01.mnh.0000186852.15889.1a

10.1002/art.20676

10.1056/NEJM199803193381202

10.1111/j.1600-6143.2005.00807.x

10.1152/ajpheart.01129.2007

Lerman A., 1991, N. Engl. J. Med., 325, 997, 10.1056/NEJM199110033251404

10.1152/ajplung.00405.2007

10.2337/db06-1406

10.1097/00041552-200201000-00009

Luscher T.F., 2000, Circulation, 102, 2434, 10.1161/01.CIR.102.19.2434

10.1038/sj.bjp.0704924

10.1038/nature06859

10.1016/S0008-6363(98)00153-9

10.1038/nature03085

10.1002/art.10895

10.1016/S0165-6147(99)01297-3

10.1016/S0140-6736(89)90303-6

Morigi M., 2005, Am. J. Pathol., 166, 1309, 10.1016/S0002-9440(10)62350-4

10.2353/ajpath.2006.051331

10.1016/j.cardiores.2006.11.019

10.1038/ki.1995.61

10.1016/S0895-7061(02)02933-3

10.1002/jcp.1041320210

10.1097/00041552-200007000-00016

Omland T., 1994, Circulation, 89, 1573, 10.1161/01.CIR.89.4.1573

Opocensky M., 2004, Physiol. Res., 53, 581

10.1161/01.HYP.0000245117.57524.d6

Orth S.R., 1999, J. Am. Soc. Nephrol., 10, 387, 10.1681/ASN.V102387

10.1093/ndt/18.1.62

10.1161/01.HYP.0000149249.09147.b4

10.1016/j.bbrc.2005.06.140

10.1016/0735-1097(95)00520-X

10.1016/S0895-7061(96)00259-2

10.2165/00003495-200161060-00003

10.1093/ndt/gfk004

10.1161/01.HYP.0000229908.62191.6e

10.1242/jcs.03073

10.1038/ncpcardio0890

Rachdaoui N., 2003, Am. J. Physiol. Endocrinol. Metab., 285, E545, 10.1152/ajpendo.00160.2003

10.1038/nrd962

10.1161/01.CIR.0000094397.19932.78

Rubanyi G.M., 1994, Pharmacol. Rev., 46, 325

Rubanyi G.M., 1985, J. Physiol., 364, 45, 10.1113/jphysiol.1985.sp015728

10.1056/NEJMoa012212

10.1513/pats.200605-111LR

10.1016/j.phrs.2004.05.009

10.1038/384353a0

Sam F., 1999, Proc. Assoc. Am. Physicians, 111, 417, 10.1111/paa.1999.111.5.417

Schiffrin E.L., 1999, Hypertension, 34, 876, 10.1161/01.HYP.34.4.876

10.1016/S0895-7061(01)02074-X

10.1016/S0895-7061(02)03006-6

10.1016/j.vph.2005.03.004

10.1161/HYPERTENSIONAHA.107.108126

10.1161/CIRCULATIONAHA.107.733212

10.1002/art.22634

10.1097/00063198-200309000-00015

Shennib H., 1998, Am. J. Respir. Crit. Care Med., 157, 1975, 10.1164/ajrccm.157.6.9709131

10.1016/j.brainres.2007.11.025

10.1016/j.cardfail.2004.01.008

10.1007/s11906-999-0075-9

10.1016/S0041-1345(98)01983-6

10.1097/00004424-200206000-00007

10.1016/0014-2999(88)90736-4

10.1097/00004872-200211000-00024

10.1016/0014-2999(88)90106-9

10.2337/db07-0893

Verhaar M.C., 1998, Circulation, 97, 752, 10.1161/01.CIR.97.8.752

Vetter D., 2006, Exp. Biol. Med. (Maywood), 231, 857

10.1097/00041552-200303000-00009

Wesson D.E., 2006, Kidney Int., 70, 2066, 10.1038/sj.ki.5001905

10.1074/jbc.274.12.8103

10.1002/art.1780340220

10.1016/0165-6147(89)90011-4

10.1038/332411a0

10.1172/JCI7447

Yokokawa K., 1991, Ann. Intern. Med., 114, 213, 10.7326/0003-4819-114-3-213

Yoshio T., 1995, Ann. Rheum. Dis., 54, 361, 10.1136/ard.54.5.361

10.1016/j.diabres.2007.12.024

Thông tin
Thông tin xuất bản

Canadian Journal of Physiology and Pharmacology

Tập 86 Số 8

485-498

Thông tin tác giả